#1
#1 out of 1
business20h ago
Vyome Holdings, Inc Announces Key Findings on VT-1953
- Vyome reports VT-1953 valued at $455 million after Phase 2, with potential to hit $1 billion post-Phase 3.
- Estimated peak U.S. sales for VT-1953 are about $600 million annually.
- The U.S. MFW treatment market is about $2.2 billion in total addressable market.
- Vyome aims for VT-1953 to be the first FDA-approved therapy for MFW symptoms.
- Destum Partners conducted the independent market analysis for Vyome.
- The summary notes the information is AI-generated and may contain inaccuracies.
- The filing cited is Vyome's 8-K dated January 28, 2026.
- The report stresses the information is based on SEC documents and should be verified.
- The release positions VT-1953 within a broader $2.2 billion MFW market in the U.S.
Vote 0